secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001999480-25-000048
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Alto Neuroscience acquires two dopamine agonist candidates for TRD and Parkinson's
--------------------------------------------------------------------------------

- Alto paid $1.75M cash plus $1.2M expense reimbursement upfront, with up to $71.5M in milestone payments ($41M commercial).
- Acquired CTC-501 (renamed ALTO-207) for treatment-resistant depression and CTC-413 (ALTO-208) for Parkinson's disease.
- Phase 2a of CTC-501 met primary endpoint; patients reached mean 4.1 mg/day, 67% achieved 5 mg, MADRS improvement d=1.1 (p=0.025).
- Alto expects to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026, with topline data in 2027.
- Cash guidance unchanged; current cash expected to fund operations into 2028 through at least five planned clinical readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/0001999480-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/alto-20250531.htm
  HTML page:      https://secwatch.observer/filing/0001999480-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer